Back to top
more

Aspen Pharmacare (APNHY)

(Delayed Data from OTC)

$13.07 USD

13.07
1,235

-0.46 (-3.41%)

Updated Aug 2, 2024 11:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for APNHY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Aspen Pharmacare falls in the month of June.

All items in Millions except Per Share data.

6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020
Assets          
Cash & Equivalents -99,999 615 407 557 457
Receivables NA 789 830 697 852
Notes Receivable NA 0 0 0 0
Inventories NA 1,106 1,037 874 1,057
Other Current Assets NA 0 0 4 0
Total Current Assets NA 2,510 2,274 2,132 2,366
Net Property & Equipment NA 1,043 1,047 967 917
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 89 82 86 110
Intangibles NA 3,875 3,860 3,880 5,050
Deposits & Other Assets NA 34 45 60 95
Total Assets NA 7,574 7,328 7,151 8,576
Liabilities & Shareholders Equity 6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020
Notes Payable NA 0 0 0 0
Accounts Payable NA 574 662 601 624
Current Portion Long-Term Debt NA 446 768 1,604 406
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 51 40 0 0
Other Current Liabilities NA 235 70 191 134
Total Current Liabilities NA 1,306 1,539 2,396 1,164
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 113 129 118 174
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 1,206 696 17 2,320
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 86 295 341 461
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 2,710 2,660 2,873 4,119
Shareholders Equity 6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 94 117 122 122
Capital Surplus NA 0 0 0 0
Retained Earnings NA 3,279 3,576 4,157 2,957
Other Equity NA 1,491 975 0 1,378
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 4,864 4,668 4,279 4,458
Total Liabilities & Shareholder's Equity NA 7,574 7,328 7,151 8,576
Total Common Equity 0 4,864 4,668 4,279 4,458
Shares Outstanding NA 446.20 446.20 456.40 456.40
Book Value Per Share 0.00 10.90 10.46 9.38 9.77

Fiscal Year End for Aspen Pharmacare falls in the month of June.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 -99,999 -99,380 -99,999 615
Receivables NA NA 719 NA 789
Notes Receivable NA NA NA NA 0
Inventories NA NA 1,012 NA 1,106
Other Current Assets NA NA NA NA 0
Total Current Assets NA NA 2,351 NA 2,510
Net Property & Equipment NA NA 1,027 NA 1,043
Investments & Advances NA NA NA NA 0
Other Non-Current Assets NA NA NA NA 0
Deferred Charges NA NA 78 NA 89
Intangibles NA NA 3,932 NA 3,875
Deposits & Other Assets NA NA 30 NA 34
Total Assets NA NA 7,438 NA 7,574
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA NA NA NA 0
Accounts Payable NA NA 565 NA 574
Current Portion Long-Term Debt NA NA 619 NA 446
Current Portion Capital Leases NA NA NA NA 0
Accrued Expenses NA NA NA NA 0
Income Taxes Payable NA NA 30 NA 51
Other Current Liabilities NA NA 11 NA 235
Total Current Liabilities NA NA 1,225 NA 1,306
Mortgages NA NA NA NA 0
Deferred Taxes/Income NA NA 100 NA 113
Convertible Debt NA NA NA NA 0
Long-Term Debt NA NA 1,309 NA 1,206
Non-Current Capital Leases NA NA NA NA 0
Other Non-Current Liabilities NA 233 NA 86
Minority Interest (Liabilities) NA NA NA NA 0
Total Liabilities NA NA 2,867 NA 2,710
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA NA NA NA 0
Common Stock (Par) NA NA 88 NA 94
Capital Surplus NA NA NA NA 0
Retained Earnings NA NA NA NA 3,279
Other Equity NA NA 4,483 NA 1,491
Treasury Stock NA NA NA NA 0
Total Shareholder's Equity NA NA 4,571 NA 4,864
Total Liabilities & Shareholder's Equity NA NA 7,438 NA 7,574
Total Common Equity 0 0 104,570 0 4,864
Shares Outstanding NA 446.20 446.20 446.20 446.20
Book Value Per Share 0.00 0.00 234.36 0.00 10.90